1 – 37 of 37
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021
2023) In Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 38(3). p.551-561(
- Contribution to journal › Article
-
Mark
Management of antineutrophil cytoplasmic antibody–associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations
(
- Contribution to journal › Scientific review
-
Mark
Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction : a multicentre study
(
- Contribution to journal › Article
-
Mark
Data quality and patient characteristics in European ANCA-associated vasculitis registries : data retrieval by federated querying
(
- Contribution to journal › Article
-
Mark
Traditional and Disease-Specific Risk Factors for Cardiovascular Events in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis : A Multinational Retrospective Study
(
- Contribution to journal › Article
- 2022
-
Mark
The management of membranous nephropathy—an update
(
- Contribution to journal › Article
-
Mark
Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease : An Open-Label Phase 2a Study
(
- Contribution to journal › Article
-
Mark
Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases : consensus statements from the ERA-IWG and EUVAS
(
- Contribution to journal › Scientific review
-
Mark
Incidence of Kidney Replacement Therapy and Subsequent Outcomes Among Patients With Systemic Lupus Erythematosus : Findings From the ERA Registry
(
- Contribution to journal › Article
- 2021
-
Mark
Plasma exchange in ANCA-associated vasculitis : the pro position
2021) In Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 36(2). p.227-231(
- Contribution to journal › Article
-
Mark
COVID-19 and ANCA-associated vasculitis : Recommendations for vaccine preparedness and the use of rituximab
(
- Contribution to journal › Letter
-
Mark
Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis : A multinational study
(
- Contribution to journal › Article
-
Mark
Rituximab in Membranous Nephropathy
(
- Contribution to journal › Scientific review
- 2020
-
Mark
Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic
(
- Contribution to journal › Article
-
Mark
Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis
(
- Contribution to journal › Article
-
Mark
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
(
- Contribution to journal › Scientific review
- 2019
-
Mark
Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis
2019) In Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 34(2). p.301-308(
- Contribution to journal › Article
-
Mark
Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe : Results From the ERA-EDTA Registry
(
- Contribution to journal › Article
-
Mark
Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status
(
- Contribution to journal › Article
- 2017
-
Mark
Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients
(
- Contribution to journal › Article
-
Mark
Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis
(
- Contribution to journal › Article
-
Mark
Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
(
- Contribution to journal › Article
-
Mark
Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Letter
- 2016
-
Mark
Rituximab for treatment of severe renal disease in ANCA associated vasculitis
(
- Contribution to journal › Article
- 2015
-
Mark
Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis.
(
- Contribution to journal › Article
-
Mark
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
(
- Contribution to journal › Article
-
Mark
Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts.
(
- Contribution to journal › Article
- 2012
-
Mark
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up
(
- Contribution to journal › Article
-
Mark
Genetically Distinct Subsets within ANCA-Associated Vasculitis
(
- Contribution to journal › Article
- 2011
-
Mark
A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis.
(
- Contribution to journal › Article
-
Mark
Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index
(
- Contribution to journal › Article
- 2010
-
Mark
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis.
(
- Contribution to journal › Article
-
Mark
EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis
(
- Contribution to journal › Article
- 2009
-
Mark
Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS
(
- Contribution to journal › Published meeting abstract
-
Mark
Pulse vs daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: a randomized controlled trial
(
- Contribution to journal › Published meeting abstract
-
Mark
Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis A Randomized Trial
(
- Contribution to journal › Article
- 2003
-
Mark
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies
(
- Contribution to journal › Article